(Q45857526)

17 December 2017

title

An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood (English)

1 reference

17 December 2017

1 reference

5

1 reference

17 December 2017

Bo Nilsson

object named as

B Nilsson

4

0 references

author name string

A Danielsson

1

1 reference

17 December 2017

G Elgue

2

1 reference

17 December 2017

B M Nilsson

3

1 reference

17 December 2017

T H Tötterman

6

1 reference

17 December 2017

S Kochanek

7

1 reference

17 December 2017

F Kreppel

8

1 reference

17 December 2017

M Essand

9

1 reference

17 December 2017

publication date

11 March 2010

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

17

1 reference

17 December 2017

issue

6

1 reference

17 December 2017

page(s)

752-762

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1038/gt.2010.18

exact match

0 references

cites work

Current developments in adenovirus-based cancer gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Oncolytic viruses in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Clinical trials with oncolytic adenovirus in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Current status of gene therapy in Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Adenovirus type 5 interactions with human blood cells may compromise systemic delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

The innate immune response to adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

The erythrocyte viral trap: transgenic expression of viral receptor on erythrocytes attenuates coxsackievirus B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Blood clearance rates of adenovirus type 5 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

CR1/2 is an important suppressor of Adenovirus-induced innate immune responses and is required for induction of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

The complement response against an oncolytic virus is species-specific in its activation pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Complement activation by recombinant adenoviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

Hydrophobic Effect and Hydrogen Bonds Account for the Improved Activity of a Complement Inhibitor, Compstatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

7 January 2021

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

7 January 2021

A transgenic mouse model for studying the clearance of blood-borne pathogens via human complement receptor 1 (CR1)

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

7 January 2021

Normal ranges for packed cell volume and hemoglobin concentration in adults: relevance to 'apparent polycythemia'

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.18

7 January 2021

Identifiers

DOI

10.1038/GT.2010.18

1 reference

17 December 2017

Dimensions Publication ID

1015791478

0 references

1 reference

17 December 2017